Q2 EPS Estimates for CVS Health Boosted by Leerink Partnrs

CVS Health Co. (NYSE:CVS) – Investment analysts at Leerink Partnrs raised their Q2 2025 EPS estimates for CVS Health in a report issued on Monday, November 18th. Leerink Partnrs analyst M. Cherny now anticipates that the pharmacy operator will post earnings of $1.71 per share for the quarter, up from their previous forecast of $1.64. The consensus estimate for CVS Health’s current full-year earnings is $5.48 per share. Leerink Partnrs also issued estimates for CVS Health’s Q3 2025 earnings at $1.81 EPS.

CVS Health (NYSE:CVS) last issued its quarterly earnings results on Wednesday, November 6th. The pharmacy operator reported $1.09 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.08 by $0.01. The company had revenue of $95.43 billion during the quarter, compared to analysts’ expectations of $92.72 billion. CVS Health had a net margin of 1.36% and a return on equity of 10.72%. CVS Health’s revenue was up 6.3% on a year-over-year basis. During the same period last year, the company posted $2.21 EPS.

Other equities research analysts also recently issued research reports about the stock. Barclays reduced their price target on shares of CVS Health from $75.00 to $71.00 and set an “overweight” rating for the company in a research report on Thursday, November 7th. Mizuho decreased their target price on shares of CVS Health from $73.00 to $66.00 and set an “outperform” rating for the company in a research note on Thursday, October 24th. Royal Bank of Canada dropped their price objective on shares of CVS Health from $68.00 to $58.00 and set an “outperform” rating on the stock in a report on Friday, November 15th. StockNews.com downgraded CVS Health from a “hold” rating to a “sell” rating in a research note on Thursday, November 14th. Finally, Deutsche Bank Aktiengesellschaft cut their price target on CVS Health from $64.00 to $63.00 and set a “hold” rating for the company in a research note on Friday, August 9th. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating and thirteen have issued a buy rating to the company. According to data from MarketBeat, CVS Health currently has a consensus rating of “Moderate Buy” and an average price target of $72.28.

CVS Health Price Performance

Shares of NYSE:CVS opened at $56.83 on Wednesday. The company has a market capitalization of $71.52 billion, a PE ratio of 14.42, a PEG ratio of 0.92 and a beta of 0.55. The business has a fifty day moving average price of $59.18 and a 200-day moving average price of $58.61. CVS Health has a 1-year low of $52.71 and a 1-year high of $83.25. The company has a debt-to-equity ratio of 0.80, a current ratio of 0.80 and a quick ratio of 0.59.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of CVS. State Street Corp grew its holdings in shares of CVS Health by 3.6% in the 3rd quarter. State Street Corp now owns 56,527,909 shares of the pharmacy operator’s stock worth $3,554,475,000 after acquiring an additional 1,989,066 shares during the last quarter. Capital World Investors raised its holdings in CVS Health by 8.0% during the 1st quarter. Capital World Investors now owns 43,776,874 shares of the pharmacy operator’s stock worth $3,491,643,000 after buying an additional 3,232,172 shares during the period. Capital International Investors boosted its holdings in shares of CVS Health by 12.5% in the first quarter. Capital International Investors now owns 37,917,923 shares of the pharmacy operator’s stock worth $3,024,334,000 after buying an additional 4,226,225 shares during the period. Geode Capital Management LLC raised its holdings in shares of CVS Health by 1.8% during the third quarter. Geode Capital Management LLC now owns 26,361,673 shares of the pharmacy operator’s stock valued at $1,651,997,000 after acquiring an additional 461,569 shares during the period. Finally, Capital Research Global Investors lifted its position in shares of CVS Health by 1.4% in the 1st quarter. Capital Research Global Investors now owns 13,143,822 shares of the pharmacy operator’s stock valued at $1,048,351,000 after acquiring an additional 184,297 shares in the last quarter. Institutional investors own 80.66% of the company’s stock.

CVS Health Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, November 1st. Shareholders of record on Monday, October 21st were issued a $0.665 dividend. The ex-dividend date of this dividend was Monday, October 21st. This represents a $2.66 dividend on an annualized basis and a yield of 4.68%. CVS Health’s dividend payout ratio is currently 67.51%.

CVS Health Company Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.